Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]D. Calebiro, V. O. Nikolaev, L. Persani and M. J. Lohse: Signaling by internalized G-protein-coupled receptors. Trends Pharmacol Sci (2010)

  • [2]S. M. Foord, T. I. Bonner, R. R. Neubig, E. M. Rosser, J. P. Pin, A. P. Davenport, M. Spedding and A. J. Harmar: International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev, 57 (2), 279-88 (2005)

  • [3]Y. Ohsawa and N. Hirasawa: The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice. Allergy, 67 (8), 1014-22 (2012)

  • [4]T. Nguyen, D. A. Shapiro, S. R. George, V. Setola, D. K. Lee, R. Cheng, L. Rauser, S. P. Lee, K. R. Lynch, B. L. Roth and B. F. O’Dowd: Discovery of a novel member of the histamine receptor family. Mol Pharmacol, 59(3), 427-33 (2001)

  • [5]T. Oda, N. Morikawa, Y. Saito, Y. Masuho and S. Matsumoto: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem, 275(47), 36781-6 (2000)

  • [6]C. Liu, X. Ma, X. Jiang, S. J. Wilson, C. L. Hofstra, J. Blevitt, J. Pyati, X. Li, W. Chai, N. Carruthers and T. W. Lovenberg: Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol, 59(3), 420-6 (2001)

  • [7]K. L. Morse, J. Behan, T. M. Laz, R. E. West, Jr., S. A. Greenfeder, J. C. Anthes, S. Umland, Y. Wan, R. W. Hipkin, W. Gonsiorek, N. Shin, E. L. Gustafson, X. Qiao, S. Wang, J. A. Hedrick, J. Greene, M. Bayne and F. J. Monsma, Jr.: Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther, 296(3), 1058-66 (2001)

  • [8]Y. Zhu, D. Michalovich, H. Wu, K. B. Tan, G. M. Dytko, I. J. Mannan, R. Boyce, J. Alston, L. A. Tierney, X. Li, N. C. Herrity, L. Vawter, H. M. Sarau, R. S. Ames, C. M. Davenport, J. P. Hieble, S. Wilson, D. J. Bergsma and L. R. Fitzgerald: Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol, 59(3), 434-41 (2001)

  • [9]R. Leurs, P. L. Chazot, F. C. Shenton, H. D. Lim and I. J. de Esch: Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol, 157(1), 14-23 (2009)

  • [10]V. A. Medina and E. S. Rivera: Histamine receptors and cancer pharmacology. Br J Pharmacol, 161(4), 755-67 (2010)

  • [11]V. Stegaev, T. Sillat, P. Porola, A. Hanninen, A. Falus, D. Mieliauskaite, E. Buzas, Z. Rotar, Z. Mackiewicz, H. Stark, P. L. Chazot and Y. T. Konttinen: Brief report: first identification of H(4) histamine receptor in healthy salivary glands and in focal sialadenitis in Sjogren’s syndrome. Arthritis Rheum, 64(8), 2663-8 (2012)

  • [12]K. Takeshita, K. Sakai, K. B. Bacon and F. Gantner: Critical role of histamine H4 receptor in leukotriene B4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. J Pharmacol Exp Ther, 307(3), 1072-8 (2003)

  • [13]R. L. Thurmond, E. W. Gelfand and P. J. Dunford: The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov, 7(1), 41-53 (2008)

  • [14]J. A. Jablonowski, N. I. Carruthers and R. L. Thurmond: The histamine H4 receptor and potential therapeutic uses for H4 ligands. Mini Rev Med Chem, 4(9), 993-1000 (2004)

  • [15]K. Rossbach, C. Nassenstein, M. Gschwandtner, D. Schnell, K. Sander, R. Seifert, H. Stark, M. Kietzmann and W. Baumer: Histamine H1, H3 and H4 receptors are involved in pruritus. Neuroscience, 190, 89-102 (2011)

  • [16]M. B. Passani and P. Blandina: Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci, 32(4), 242-9 (2011)

  • [17]C. Salcedo, C. Pontes and M. Merlos: Is the H4 receptor a new drug target for allergies and asthma? Front Biosci (Elite Ed), 5, 178-87 (2013)

  • [18]M. Andaloussi, H. D. Lim, T. van der Meer, M. Sijm, C. B. Poulie, I. J. de Esch, R. Leurs and R. A. Smits: A novel series of histamine H4 receptor antagonists based on the pyrido(3,2-d)pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787. Bioorg Med Chem Lett, 23(9), 2663-70 (2013)

  • [19]J. M. Cowden, F. Yu, M. Challapalli, J. F. Huang, S. Kim, W. P. Fung-Leung, J. Y. Ma, J. P. Riley, M. Zhang, P. J. Dunford and R. L. Thurmond: Antagonism of the histamine H4 receptor reduces LPS-induced TNF production in vivo. Inflamm Res, 62(6), 599-607 (2013)

  • [20]M. Gschwandtner, B. Koether, T. Werfel, H. Stark and R. Gutzmer: Profiling of histamine H4 receptor agonists in native human monocytes. Br J Pharmacol, 170(1), 136-43 (2013)

  • [21]M. Zhang, R. L. Thurmond and P. J. Dunford: The histamine H(4) receptor: a novel modulator of inflammatory and immune disorders. Pharmacol Ther, 113(3), 594-606 (2007)

  • [22]M. Zhang, J. D. Venable and R. L. Thurmond: The histamine H4 receptor in autoimmune disease. Expert Opin Investig Drugs, 15(11), 1443-52 (2006)

  • [23]R. A. Smits, H. D. Lim, B. Stegink, R. A. Bakker, I. J. de Esch and R. Leurs: Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives. J Med Chem, 49(15), 4512-6 (2006)

  • [24]H. D. Lim, R. M. van Rijn, P. Ling, R. A. Bakker, R. L. Thurmond and R. Leurs: Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther, 314(3), 1310-21 (2005)

  • [25]T. Hashimoto, S. Harusawa, L. Araki, O. P. Zuiderveld, M. J. Smit, T. Imazu, S. Takashima, Y. Yamamoto, Y. Sakamoto, T. Kurihara, R. Leurs, R. A. Bakker and A. Yamatodani: A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-((2R,5R)-5-(1H-imidazol-4(5)-yl)tetrahydrofuran-2-y) methylguanidine. J Med Chem, 46(14), 3162-5 (2003)

  • [26]Y. Sugata, M. Okano, T. Fujiwara, R. Matsumoto, H. Hattori, M. Yamamoto, M. Nishibori and K. Nishizaki: Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology, 121(2), 266-75 (2007)

  • [27]P. Igel, R. Geyer, A. Strasser, S. Dove, R. Seifert and A. Buschauer: Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists. J Med Chem, 52(20), 6297-313 (2009)

  • [28]H. D. Lim, R. A. Smits, R. A. Bakker, C. M. van Dam, I. J. de Esch and R. Leurs: Discovery of S-(2-guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist. J Med Chem, 49(23), 6650-1 (2006)

  • [29]V. Katritch, V. Cherezov and R. C. Stevens: Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci, 33(1), 17-27 (2012)

  • [30]D. J. Muller, N. Wu and K. Palczewski: Vertebrate membrane proteins: structure, function, and insights from biophysical approaches. Pharmacol Rev, 60(1), 43-78 (2008)

  • [31]X. Deupi, J. Standfuss and G. Schertler: Conserved activation pathways in G-protein-coupled receptors. Biochem Soc Trans, 40(2), 383-8 (2012)

  • [32]U. Gether: Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev, 21(1), 90-113 (2000)

  • [33]E. Zampeli and E. Tiligada: The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol, 157(1), 24-33 (2009)

  • [34]B. Nurnberg, T. Gudermann and G. Schultz: Receptors and G proteins as primary components of transmembrane signal transduction. Part 2. G proteins: structure and function. J Mol Med, 73(3), 123-32 (1995)

  • [35]J. Drews: Drug discovery: a historical perspective. Science, 287(5460), 1960-4 (2000)

  • [36]P. Nambi and N. Aiyar: G protein-coupled receptors in drug discovery. Assay Drug Dev Technol, 1(2), 305-10 (2003)

  • [37]J. P. Overington, B. Al-Lazikani and A. L. Hopkins: How many drug targets are there? Nat Rev Drug Discov, 5(12), 993-6 (2006)

  • [38]A. Rayan: New vistas in GPCR 3D structure prediction. J Mol Model, 16(2), 183-91 (2010)

  • [39]S. Ananthan, W. Zhang and J. V. Hobrath: Recent advances in structure-based virtual screening of G-protein coupled receptors. Aaps J, 11(1), 178-85 (2009)

  • [40]A. Patny, P. V. Desai and M. A. Avery: Homology modeling of G-protein-coupled receptors and implications in drug design. Curr Med Chem, 13(14), 1667-91 (2006)

  • [41]P. L. Yeagle and A. D. Albert: G-protein coupled receptor structure. Biochim Biophys Acta, 1768(4), 808-24 (2007)

  • [42]W. Kuhlbrandt and E. Gouaux: Membrane proteins. Curr Opin Struct Biol, 9(4), 445-7 (1999)

  • [43]K. Palczewski, T. Kumasaka, T. Hori, C. A. Behnke, H. Motoshima, B. A. Fox, I. Le Trong, D. C. Teller, T. Okada, R. E. Stenkamp, M. Yamamoto and M. Miyano: Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 289(5480), 739-45 (2000)

  • [44]T. Warne, M. J. Serrano-Vega, J. G. Baker, R. Moukhametzianov, P. C. Edwards, R. Henderson, A. G. Leslie, C. G. Tate and G. F. Schertler: Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 454(7203), 486-91 (2008)

  • [45]V. Cherezov, D. M. Rosenbaum, M. A. Hanson, S. G. Rasmussen, F. S. Thian, T. S. Kobilka, H. J. Choi, P. Kuhn, W. I. Weis, B. K. Kobilka and R. C. Stevens: High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 318(5854), 1258-65 (2007)

  • [46]V. P. Jaakola, M. T. Griffith, M. A. Hanson, V. Cherezov, E. Y. Chien, J. R. Lane, A. P. Ijzerman and R. C. Stevens: The 2.6. angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 322(5905), 1211-7 (2008)

  • [47]T. Shimamura, M. Shiroishi, S. Weyand, H. Tsujimoto, G. Winter, V. Katritch, R. Abagyan, V. Cherezov, W. Liu, G. W. Han, T. Kobayashi, R. C. Stevens and S. Iwata: Structure of the human histamine H1 receptor complex with doxepin. Nature, 475(7354), 65-70 (2011)

  • [48]M. A. Hanson, C. B. Roth, E. Jo, M. T. Griffith, F. L. Scott, G. Reinhart, H. Desale, B. Clemons, S. M. Cahalan, S. C. Schuerer, M. G. Sanna, G. W. Han, P. Kuhn, H. Rosen and R. C. Stevens: Crystal structure of a lipid G protein-coupled receptor. Science, 335(6070), 851-5 (2012)

  • [49]E. Y. Chien, W. Liu, Q. Zhao, V. Katritch, G. W. Han, M. A. Hanson, L. Shi, A. H. Newman, J. A. Javitch, V. Cherezov and R. C. Stevens: Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science, 330(6007), 1091-5 (2010)

  • [50]B. Wu, E. Y. Chien, C. D. Mol, G. Fenalti, W. Liu, V. Katritch, R. Abagyan, A. Brooun, P. Wells, F. C. Bi, D. J. Hamel, P. Kuhn, T. M. Handel, V. Cherezov and R. C. Stevens: Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science, 330(6007), 1066-71 (2010)

  • [51]K. Haga, A. C. Kruse, H. Asada, T. Yurugi-Kobayashi, M. Shiroishi, C. Zhang, W. I. Weis, T. Okada, B. K. Kobilka, T. Haga and T. Kobayashi: Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature, 482(7386), 547-51 (2012)

  • [52]A. C. Kruse, J. Hu, A. C. Pan, D. H. Arlow, D. M. Rosenbaum, E. Rosemond, H. F. Green, T. Liu, P. S. Chae, R. O. Dror, D. E. Shaw, W. I. Weis, J. Wess and B. K. Kobilka: Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature, 482(7386), 552-6 (2012)

  • [53]H. Wu, D. Wacker, M. Mileni, V. Katritch, G. W. Han, E. Vardy, W. Liu, A. A. Thompson, X. P. Huang, F. I. Carroll, S. W. Mascarella, R. B. Westkaemper, P. D. Mosier, B. L. Roth, V. Cherezov and R. C. Stevens: Structure of the human kappa-opioid receptor in complex with JDTic. Nature, 485(7398), 327-32 (2012)

  • [54]A. Manglik, A. C. Kruse, T. S. Kobilka, F. S. Thian, J. M. Mathiesen, R. K. Sunahara, L. Pardo, W. I. Weis, B. K. Kobilka and S. Granier: Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature, 485(7398), 321-6 (2012)

  • [55]S. Granier, A. Manglik, A. C. Kruse, T. S. Kobilka, F. S. Thian, W. I. Weis and B. K. Kobilka: Structure of the delta-opioid receptor bound to naltrindole. Nature, 485(7398), 400-4 (2012)

  • [56]C. Zhang, Y. Srinivasan, D. H. Arlow, J. J. Fung, D. Palmer, Y. Zheng, H. F. Green, A. Pandey, R. O. Dror, D. E. Shaw, W. I. Weis, S. R. Coughlin and B. K. Kobilka: High-resolution crystal structure of human protease-activated receptor 1. Nature, 492(7429), 387-92 (2012)

  • [57]J. F. White, N. Noinaj, Y. Shibata, J. Love, B. Kloss, F. Xu, J. Gvozdenovic-Jeremic, P. Shah, J. Shiloach, C. G. Tate and R. Grisshammer: Structure of the agonist-bound neurotensin receptor. Nature, 490(7421), 508-13 (2012)

  • [58]J. Zhang, K. Zhang, Z. G. Gao, S. Paoletta, D. Zhang, G. W. Han, T. Li, L. Ma, W. Zhang, C. E. Muller, H. Yang, H. Jiang, V. Cherezov, V. Katritch, K. A. Jacobson, R. C. Stevens, B. Wu and Q. Zhao: Agonist-bound structure of the human P2Y12 receptor. Nature, 509(7498), 119-22 (2014)

  • [59]A. A. Thompson, W. Liu, E. Chun, V. Katritch, H. Wu, E. Vardy, X. P. Huang, C. Trapella, R. Guerrini, G. Calo, B. L. Roth, V. Cherezov and R. C. Stevens: Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature, 485(7398), 395-9 (2012)

  • [60]B. Jastrzebska, K. Palczewski and M. Golczak: Role of bulk water in hydrolysis of the rhodopsin chromophore. J Biol Chem, 286(21), 18930-7 (2011)

  • [61]T. Orban, B. Jastrzebska, S. Gupta, B. Wang, M. Miyagi, M. R. Chance and K. Palczewski: Conformational dynamics of activation for the pentameric complex of dimeric G protein-coupled receptor and heterotrimeric G protein. Structure, 20(5), 826-40 (2012)

  • [62]S. G. Rasmussen, B. T. DeVree, Y. Zou, A. C. Kruse, K. Y. Chung, T. S. Kobilka, F. S. Thian, P. S. Chae, E. Pardon, D. Calinski, J. M. Mathiesen, S. T. Shah, J. A. Lyons, M. Caffrey, S. H. Gellman, J. Steyaert, G. Skiniotis, W. I. Weis, R. K. Sunahara and B. K. Kobilka: Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature, 477(7366), 549-55 (2011)

  • [63]D. Latek, A. Modzelewska, B. Trzaskowski, K. Palczewski and S. Filipek: G protein-coupled receptors--recent advances. Acta Biochim Pol, 59(4), 515-29 (2012)

  • [64]K. Palczewski: Chemistry and biology of vision. J Biol Chem, 287(3), 1612-9 (2012)

  • [65]J. Standfuss, G. Xie, P. C. Edwards, M. Burghammer, D. D. Oprian and G. F. Schertler: Crystal structure of a thermally stable rhodopsin mutant. J Mol Biol, 372(5), 1179-88 (2007)

  • [66]S. J. Fleishman, V. M. Unger and N. Ben-Tal: Transmembrane protein structures without X-rays. Trends Biochem Sci, 31(2), 106-13 (2006)

  • [67]V. R. Ratnala: New tools for G-protein coupled receptor (GPCR) drug discovery: combination of baculoviral expression system and solid state NMR. Biotechnol Lett, 28(11), 767-78 (2006)

  • [68]N. Nielsen, A. Malmendal and T. Vosegaard: Techniques and applications of NMR to membrane proteins. Mol Membr Biol, 21(3), 129-41 (2004)

  • [69]C. R. Sanders and F. Sonnichsen: Solution NMR of membrane proteins: practice and challenges. Magn Reson Chem, 44 Spec No, S24-40 (2006)

  • [70]L. Shi, M. M. Simpson, J. A. Ballesteros and J. A. Javitch: The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry, 40(41), 12339-48 (2001)

  • [71]J. A. Javitch, L. Shi, M. M. Simpson, J. Chen, V. Chiappa, I. Visiers, H. Weinstein and J. A. Ballesteros: The fourth transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry, 39(40), 12190-9 (2000)

  • [72]O. J. Kim: A single mutation at lysine 241 alters expression and trafficking of the D2 dopamine receptor. J Recept Signal Transduct Res, 28(5), 453-64 (2008)

  • [73]A. Kapur, P. Samaniego, G. A. Thakur, A. Makriyannis and M. E. Abood: Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther, 325(1), 341-8 (2008)

  • [74]T. H. Ji, M. Grossmann and I. Ji: G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J Biol Chem, 273(28), 17299-302 (1998)

  • [75]A. Woehler and E. G. Ponimaskin: G protein--mediated signaling: same receptor, multiple effectors. Curr Mol Pharmacol, 2(3), 237-48 (2009)

  • [76]C. B. Anfinsen and H. A. Scheraga: Experimental and theoretical aspects of protein folding. Adv Protein Chem, 29, 205-300 (1975)

  • [77]A. Rayan: New tips for structure prediction by comparative modeling. Bioinformation, 3(6), 263-7 (2009)

  • [78]S. Topiol and M. Sabio: X-ray structure breakthroughs in the GPCR transmembrane region. Biochem Pharmacol, 78(1), 11-20 (2009)

  • [79]G. F. Schertler and P. A. Hargrave: Projection structure of frog rhodopsin in two crystal forms. Proc Natl Acad Sci U S A, 92(25), 11578-82 (1995)

  • [80]R. J. Trabanino, S. E. Hall, N. Vaidehi, W. B. Floriano, V. W. Kam and W. A. Goddard, 3rd: First principles predictions of the structure and function of g-protein-coupled receptors: validation for bovine rhodopsin. Biophys J, 86(4), 1904-21 (2004)

  • [81]S. G. Rasmussen, H. J. Choi, D. M. Rosenbaum, T. S. Kobilka, F. S. Thian, P. C. Edwards, M. Burghammer, V. R. Ratnala, R. Sanishvili, R. F. Fischetti, G. F. Schertler, W. I. Weis and B. K. Kobilka: Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature, 450(7168), 383-7 (2007)

  • [82]M. Punta, L. R. Forrest, H. Bigelow, A. Kernytsky, J. Liu and B. Rost: Membrane protein prediction methods. Methods, 41(4), 460-74 (2007)

  • [83]L. R. Forrest, C. L. Tang and B. Honig: On the accuracy of homology modeling and sequence alignment methods applied to membrane proteins. Biophys J, 91(2), 508-17 (2006)

  • [84]G. V. Nikiforovich and G. R. Marshall: Modeling flexible loops in the dark-adapted and activated states of rhodopsin, a prototypical G-protein-coupled receptor. Biophys J, 89(6), 3780-9 (2005)

  • [85]E. L. Mehler, S. A. Hassan, S. Kortagere and H. Weinstein: Ab initio computational modeling of loops in G-protein-coupled receptors: lessons from the crystal structure of rhodopsin. Proteins, 64(3), 673-90 (2006)

  • [86]A. Rayan, E. Noy, D. Chema, A. Levitzki and A. Goldblum: Stochastic algorithm for kinase homology model construction. Curr Med Chem, 11(6), 675-92 (2004)

  • [87]A. Rayan, H. Senderowitz and A. Goldblum: Exploring the conformational space of cyclic peptides by a stochastic search method. J Mol Graph Model, 22(5), 319-33 (2004)

  • [88]G. Porwal, S. Jain, S. D. Babu, D. Singh, H. Nanavati and S. Noronha: Protein structure prediction aided by geometrical and probabilistic constraints. J Comput Chem, 28(12), 1943-52 (2007)

  • [89]R. Srinivasan and G. D. Rose: Ab initio prediction of protein structure using LINUS. Proteins, 47(4), 489-95 (2002)

  • [90]S. Wu, J. Skolnick and Y. Zhang: Ab initio modeling of small proteins by iterative TASSER simulations. BMC Biol, 5, 17 (2007)

  • [91]A. Rayan, N. Siew, S. Cherno-Schwartz, Y. Matzner, W. Bautsch and A. Goldblum: A novel computational method for predicting the transmembrane structure of G-protein coupled receptors: application to human C5aR and C3aR. Receptors Channels, 7(2), 121-37 (2000)

  • [92]A. Tramontano and V. Morea: Assessment of homology-based predictions in CASP5. Proteins, 53 Suppl 6, 352-68 (2003)

  • [93]B. M. Broer, M. Gurrath and H. D. Holtje: Molecular modelling studies on the ORL1-receptor and ORL1-agonists. J Comput Aided Mol Des, 17(11), 739-54 (2003)

  • [94]G. D. Chandramoorthi, S. Piramanayagam and P. Marimuthu: An insilico approach to high altitude pulmonary edema - Molecular modeling of human beta2 adrenergic receptor and its interaction with Salmeterol & Nifedipine. J Mol Model, 14(9), 849-56 (2008)

  • [95]E. Hazai and Z. Bikadi: Homology modeling of breast cancer resistance protein (ABCG2). J Struct Biol, 162(1), 63-74 (2008)

  • [96]M. Li, H. Fang, L. Du, L. Xia and B. Wang: Computational studies of the binding site of alpha1A-adrenoceptor antagonists. J Mol Model, 14(10), 957-66 (2008)

  • [97]B. Schlegel, C. Laggner, R. Meier, T. Langer, D. Schnell, R. Seifert, H. Stark, H. D. Holtje and W. Sippl: Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des, 21(8), 437-53 (2007)

  • [98]G. Kleinau, M. Brehm, U. Wiedemann, D. Labudde, U. Leser and G. Krause: Implications for molecular mechanisms of glycoprotein hormone receptors using a new sequence-structure-function analysis resource. Mol Endocrinol, 21(2), 574-80 (2007)

  • [99]G. Kleinau, M. Claus, H. Jaeschke, S. Mueller, S. Neumann, R. Paschke and G. Krause: Contacts between extracellular loop two and transmembrane helix six determine basal activity of the thyroid-stimulating hormone receptor. J Biol Chem, 282(1), 518-25 (2007)

  • [100]L. Oliveira, A. C. Paiva and G. Vriend: Correlated mutation analyses on very large sequence families. Chembiochem, 3(10), 1010-7 (2002)

  • [101]S. Shacham, M. Topf, N. Avisar, F. Glaser, Y. Marantz, S. Bar-Haim, S. Noiman, Z. Naor and O. M. Becker: Modeling the 3D structure of GPCRs from sequence. Med Res Rev, 21(5), 472-83 (2001)

  • [102]D. Baker and A. Sali: Protein structure prediction and structural genomics. Science, 294(5540), 93-6 (2001)

  • [103]J. M. Baldwin, G. F. Schertler and V. M. Unger: An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol, 272(1), 144-64 (1997)

  • [104]T. Mirzadegan, G. Benko, S. Filipek and K. Palczewski: Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry, 42(10), 2759-67 (2003)

  • [105]G. Lebon, T. Warne, P. C. Edwards, K. Bennett, C. J. Langmead, A. G. Leslie and C. G. Tate: Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature, 474(7352), 521-5 (2011)

  • [106]S. G. Rasmussen, H. J. Choi, J. J. Fung, E. Pardon, P. Casarosa, P. S. Chae, B. T. Devree, D. M. Rosenbaum, F. S. Thian, T. S. Kobilka, A. Schnapp, I. Konetzki, R. K. Sunahara, S. H. Gellman, A. Pautsch, J. Steyaert, W. I. Weis and B. K. Kobilka: Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature, 469(7329), 175-80 (2011)

  • [107]A. M. Ring, A. Manglik, A. C. Kruse, M. D. Enos, W. I. Weis, K. C. Garcia and B. K. Kobilka: Adrenaline-activated structure of beta2-adrenoceptor stabilized by an engineered nanobody. Nature, 502(7472), 575-9 (2013)

  • [108]J. Standfuss, P. C. Edwards, A. D’Antona, M. Fransen, G. Xie, D. D. Oprian and G. F. Schertler: The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature, 471(7340), 656-60 (2011)

  • [109]F. Fanelli and P. G. De Benedetti: Inactive and active states and supramolecular organization of GPCRs: insights from computational modeling. J Comput Aided Mol Des, 20(7-8), 449-61 (2006)

  • [110]F. Fanelli and D. Dell’Orco: Rhodopsin activation follows precoupling with transducin: inferences from computational analysis. Biochemistry, 44(45), 14695-700 (2005)

  • [111]P. R. Gouldson, N. J. Kidley, R. P. Bywater, G. Psaroudakis, H. D. Brooks, C. Diaz, D. Shire and C. A. Reynolds: Toward the active conformations of rhodopsin and the beta2-adrenergic receptor. Proteins, 56(1), 67-84 (2004)

  • [112]B. Isin, A. J. Rader, H. K. Dhiman, J. Klein-Seetharaman and I. Bahar: Predisposition of the dark state of rhodopsin to functional changes in structure. Proteins, 65(4), 970-83 (2006)

  • [113]J. C. Mobarec and M. Filizola: Advances in the Development and Application of Computational Methodologies for Structural Modeling of G-Protein Coupled Receptors. Expert Opin Drug Discov, 3(3), 343-355 (2008)

  • [114]M. Y. Niv, L. Skrabanek, M. Filizola and H. Weinstein: Modeling activated states of GPCRs: the rhodopsin template. J Comput Aided Mol Des, 20(7-8), 437-48 (2006)

  • [115]N. Shin, E. Coates, N. J. Murgolo, K. L. Morse, M. Bayne, C. D. Strader and F. J. Monsma, Jr.: Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. Mol Pharmacol, 62(1), 38-47 (2002)

  • [116]R. Kiss, B. Kiss, A. Konczol, F. Szalai, I. Jelinek, V. Laszlo, B. Noszal, A. Falus and G. M. Keseru: Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem, 51(11), 3145-53 (2008)

  • [117]A. Evers and T. Klabunde: Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J Med Chem, 48(4), 1088-97 (2005)

  • [118]A. Evers and G. Klebe: Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J Med Chem, 47(22), 5381-92 (2004)

  • [119]J. Varady, X. Wu, X. Fang, J. Min, Z. Hu, B. Levant and S. Wang: Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore-and structure-based database searching approach. J Med Chem, 46(21), 4377-92 (2003)

  • [120]A. Jongejan, H. D. Lim, R. A. Smits, I. J. de Esch, E. Haaksma and R. Leurs: Delineation of agonist binding to the human histamine H4 receptor using mutational analysis, homology modeling, and ab initio calculations. J Chem Inf Model, 48(7), 1455-63 (2008)

  • [121]H. Buyukuslu, M. Akdogan, G. Yildirim and C. Parlak: Ab initio Hartree-Fock and density functional theory study on characterization of 3-(5-methylthiazol-2-yldiazenyl)-2-phenyl-1H-indole. Spectrochim Acta A Mol Biomol Spectrosc, 75(4), 1362-9 (2010)

  • [122]B. Jojart, R. Kiss, B. Viskolcz and G. M. Keseru: Activation mechanism of the human histamine H4 receptor--an explicit membrane molecular dynamics simulation study. J Chem Inf Model, 48(6), 1199-210 (2008)

  • [123]R. Kiss, B. Noszal, A. Racz, A. Falus, D. Eros and G. M. Keseru: Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor. Eur J Med Chem, 43(5), 1059-70 (2008)

  • [124]S. Harusawa, L. Araki, T. Imazu, H. Ohishi, Y. Sakamoto and T. Kurihara: Synthesis of (+/-)-trans-or cis-(5-aminomethyltetrahydrofuranyl)imidazole by Mitsunobu cyclization: synthetic studies toward novel histamine H3 or H4-ligands. Chem Pharm Bull (Tokyo), 51(3), 325-9 (2003)

  • [125]J. A. Jablonowski, C. A. Grice, W. Chai, C. A. Dvorak, J. D. Venable, A. K. Kwok, K. S. Ly, J. Wei, S. M. Baker, P. J. Desai, W. Jiang, S. J. Wilson, R. L. Thurmond, L. Karlsson, J. P. Edwards, T. W. Lovenberg and N. I. Carruthers: The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem, 46(19), 3957-60 (2003)

  • [126]G. Pugalenthi, K. Shameer, N. Srinivasan and R. Sowdhamini: HARMONY: a server for the assessment of protein structures. Nucleic Acids Res, 34(Web Server issue), W231-4 (2006)

  • [127]H. D. Lim, A. Jongejan, R. A. Bakker, E. Haaksma, I. J. de Esch and R. Leurs: Phenylalanine 169 in the second extracellular loop of the human histamine H4 receptor is responsible for the difference in agonist binding between human and mouse H4 receptors. J Pharmacol Exp Ther, 327(1), 88-96 (2008)

  • [128]K. F. Deml, S. Beermann, D. Neumann, A. Strasser and R. Seifert: Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor. Mol Pharmacol, 76(5), 1019-30 (2009)

  • [129]A. Strasser and H. J. Wittmann: Analysis of the activation mechanism of the guinea-pig Histamine H1-receptor. J Comput Aided Mol Des, 21(9), 499-509 (2007)

  • [130]E. P. Istyastono, S. Nijmeijer, H. D. Lim, A. van de Stolpe, L. Roumen, A. J. Kooistra, H. F. Vischer, I. J. de Esch, R. Leurs and C. de Graaf: Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies. J Med Chem, 54(23), 8136-47 (2011)

  • [131]J. Levita, N. M. Saptarini and A. Ardiansyah: Generating a 3D structure model of Histamine receptor for Antiinflammatory Drug Design, 32 (2), 22-7 (2012)

  • [132]F. Christopher, E. B. Thangam and M. X. Suresh: A bioinformatics search for selective histamine h4 receptor antagonists through structure-based virtual screening strategies. Chem Biol Drug Des, 79(5), 749-59 (2012)

  • [133]A. A. Vaguine, J. Richelle and S. J. Wodak: SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr D Biol Crystallogr, 55(Pt 1), 191-205 (1999)

  • [134]C. Colovos and T. O. Yeates: Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci, 2(9), 1511-9 (1993)

  • [135]Z. Feng, T. Hou and Y. Li: Docking and MD study of histamine H4R based on the crystal structure of H1R. J Mol Graph Model, 39, 1-12 (2013)

  • [136]M. Vass, E. Schmidt, F. Horti and G. M. Keseru: Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. Eur J Med Chem, 77, 38-46 (2014)

  • [137]S. Schultes, H. Engelhardt, L. Roumen, O. P. Zuiderveld, E. E. Haaksma, I. J. de Esch, R. Leurs and C. de Graaf: Combining quantum mechanical ligand conformation analysis and protein modeling to elucidate GPCR-ligand binding modes. ChemMedChem, 8(1), 49-53 (2013)

  • [138]S. Schultes, S. Nijmeijer, H. Engelhardt, A. J. Kooistra, H. F. vischer, I. J. de Esch, E. E. Haaksma, R. Leurs and C. de Graaf: Mapping histamine H4 receptor-ligand binding modes. Medchemcomm, 4, 193-204 (2013)

  • [139]H. Engelhardt, S. Schultes, C. de Graaf, S. Nijmeijer, H. F. Vischer, O. P. Zuiderveld, J. Dobler, K. Stachurski, M. Mayerk2, H. Arnhof, D. Scharn, E. E. Haaksma, I. J. de Esch and R. Leurs: Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding mode. J Med Chem, 56(11), 4264-76 (2013)

  • [140]O. Korb, T. Stutzle and T. E. Exner: Empirical scoring functions for advanced protein-ligand docking with PLANTS. J Chem Inf Model, 49(1), 84-96 (2009)

  • [141]M. Pappalardo, N. Shachaf, L. Basile, D. Milardi, M. Zeidan, J. Raiyn, S. Guccione and A. Rayan: Sequential application of ligand and structure based modeling approaches to index chemicals for their hH4R antagonism. PLoS One, 9(10), 1-15 (2014)

  • [142]A. Rayan: The utility of Intelligent Learning Engine in Drug Discovery Informatics. Proceedings of the British Pharmacological Society, 7(4), 26 (2010)

  • [143]A. Rayan, M. Falah, J. Raiyn, B. Da’adoosh, S. Kadan, H. Zaid and A. Goldblum: Indexing molecules for their hERG liability. Eur J Med Chem, 65, 304-14 (2013)

  • [144]A. Rayan, D. Marcus and A. Goldblum: Predicting oral druglikeness by iterative stochastic elimination. J Chem Inf Model, 50(3), 437-45 (2010)

  • [145]J. J. Irwin, T. Sterling, M. M. Mysinger, E. S. Bolstad and R. G. Coleman: ZINC: a free tool to discover chemistry for biology. J Chem Inf Model, 52(7), 1757-68 (2012)

  • [146]Y. Tanrikulu, E. Proschak, T. Werner, T. Geppert, N. Todoroff, A. Klenner, T. Kottke, K. Sander, E. Schneider, R. Seifert, H. Stark, T. Clark and G. Schneider: Homology model adjustment and ligand screening with a pseudoreceptor of the human histamine H4 receptor. ChemMedChem, 4(5), 820-7 (2009)

  • [147]W. A. Goddard, 3rd, S. K. Kim, Y. Li, B. Trzaskowski, A. R. Griffith and R. Abrol: Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. J Struct Biol, 170(1), 10-20 (2010)

  • [148]W. B. Floriano, N. Vaidehi, W. A. Goddard, 3rd, M. S. Singer and G. M. Shepherd: Molecular mechanisms underlying differential odor responses of a mouse olfactory receptor. Proc Natl Acad Sci U S A, 97(20), 10712-6 (2000)

  • [149]J. K. Bray and W. A. Goddard, 3rd: The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists. J Mol Graph Model, 27(1), 66-81 (2008)

  • [150]S. K. Kim, Y. Li, C. Park, R. Abrol and W. A. Goddard, 3rd: Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations. ChemMedChem, 5(9), 1594-608 (2010)

  • [151]E. H. Schneider, D. Schnell, A. Strasser, S. Dove and R. Seifert: Impact of the DRY motif and the missing “ionic lock” on constitutive activity and G-protein coupling of the human histamine H4 receptor. J Pharmacol Exp Ther, 333(2), 382-92 (2010)

  • [152]P. Scheerer, J. H. Park, P. W. Hildebrand, Y. J. Kim, N. Krauss, H. W. Choe, K. P. Hofmann and O. P. Ernst: Crystal structure of opsin in its G-protein-interacting conformation. Nature, 455(7212), 497-502 (2008)

  • [153]J. P. Fernandes, K. F. Pasqualoto, E. I. Ferreira and C. A. Brandt: Molecular modeling and QSAR studies of a set of indole and benzimidazole derivatives as H(4) receptor antagonists. J Mol Model, 17(5), 921-8 (2011)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Review

In silico modeling techniques for predicting the tertiary structure of human H4 receptor

Hilal Zaid 1, Jamal Raiyn 2, Midhat Osman 1, Mizied Falah 1, Samer Srouji 3, Anwar Rayan 1,4,*
Affiliations
Article Info

1 Drug Discovery Informatics Lab, QRC - Qasemi Research Center, Al-Qasemi Academic College, Baka EL-Garbiah 30100, Israel

2 Computer Science Department, Al-Qasemi Academic College, Baka EL-Garbiah 30100, Israel

3 Bone Regeneration Lab, Oral and Maxillofacial Surgery Department, Galilee Medical Center, Nahariya 22100, Israel

4 Science Education Department, Al-Qasemi Academic College, Baka EL-Garbiah 30100, Israel

Abstract

First cloned in 2000, the human Histamine H4 Receptor (hH4R) is the last member of the histamine receptors family discovered so far, it belongs to the GPCR super-family and is involved in a wide variety of immunological and inflammatory responses. Potential hH4R antagonists are proposed to have therapeutic potential for the treatment of allergies, inflammation, asthma and colitis. So far, no hH4R ligands have been successfully introduced to the pharmaceutical market, which creates a strong demand for new selective ligands to be developed. In silico techniques and structural based modeling are likely to facilitate the achievement of this goal. In this review paper we attempt to cover the fundamental concepts of hH4R structure modeling and its implementations in drug discovery and development, especially those that have been experimentally tested and to highlight some ideas that are currently being discussed on the dynamic nature of hH4R and GPCRs, in regards to computerized techniques for 3-D structure modeling.

Keywords

  • H4R-H4 receptor
  • homology modeling
  • 3D-structure prediction
  • G-protein coupled receptors (GPCRs)
  • Drug Discovery
  • Review

References